Five Pot Stocks On The ASX – AC8, CAN, CPH, MMJ and THC

3 min read | January 16, 2019 08:04 PM AEDT | By Team Kalkine Media

Google News:

Five Pot Stocks On The ASX – AC8, CAN, CPH, MMJ and THC

Recent News

Why Is ASX 300 Medicinal Cannabis Gaining Momentum?

US Cannabis Reform and ASX 300: ASX Pot Stock Sector Guide

When Markets Get Scary, Why Do Investors Run Toward ASX Blue Chips?

ASX Blue-Chip Valuations Across ASX 100 Market Leaders

Make Kalkine Media
My Trusted Source

The pot stocks still have the potential for growth and the legal marijuana industry is expected to increase in 2019. While on one hand pot stocks have not performed up to the expectations set in the last year and the stock prices have gone down after a surge in local pot stocks on the new year beginning in 2018. On the other side, Mark Bernberg an investment strategist has launched the first cannabis investment consultancy in Australia, which according to him is a Green Fund.

According to research, the sales of medical Cannabis are expected to reach $75 billion by 2030. And investors could make huge gains in this space. However, some analysts have different view on the green rush and state that the cannabis industry is a small area which became a talking point for some time and is now fading away. Especially after the legalization of the same in Canada, the focus shifted from Australia.

As the relaxation continues in the Americas, the popular view is that it is the right time to invest in Cannabis stocks. Other than Australia few others in Asia Pacific region like South Korea and Thailand have also followed the same path of legalizing medical cannabis. Few of the stocks in this industry in Australia are as follows.

Auscann Group Holdings Ltd (ASX: AC8) â The stock price went up by approx. 2.013% to trade at $0.760. The company recently gives an update on the Companyâs CEO transition. The returns in 1 year have been of concern with -58.61% plunge on the ASX.

Cann Group Limited (ASX: CAN) â The stock price has gone up by 1.914% to trade at $2.130. The returns in 1 year have been of concern with -39.42% plunge on the ASX.

Creso Pharma Limited (ASX: CPH) â The stock price has gone down by 2.778% to trade at $0.525. The returns in 1 year have been of concern with -49.53% plunge on the ASX. On building a comprehensive cannabis business in New Zealand, the company has signed a Letter of Intent with Medleaf Ltd.

MMJ Group Holdings Limited (ASX: MMJ) â The stock price has gone down by -5.455% to trade at $0.260. The returns in 1 year have been of concern with -44.44% plunge on the ASX. The company recently confirms that its unaudited NTA per share was 22.48 cents (pre-tax) and 21.16 cents (post-tax) as at December 31, 2018.

THC Global Group Limited (ASX: THC) â The stock price has gone up by 2% to trade at $0.510. The returns in 1 year have been of concern with -45.05% plunge on the ASX.

Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.